ClinicalTrials.gg
Active, not recruitingNCT06928142EnVISageUpdated Nov 13, 2026

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

A Phase 2 interventional study of Sibeprenlimab and Placebo in Sjogren Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Active, not recruiting at 63 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Nov 13, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.

Enrollment
87th of 243
83 · median 53
Started
2025
with 22 others
Phase 2
75 of 341
13 open now
Primary completion
2027-03
later than 30 of 111 live
Registered
310th of 341
by date

Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 87th largest by enrollment of the 243 interventional ones that give a count, is one of 23 that started in 2025, is one of 75 in phase 2, reaches primary completion later than 30 of the 111 other live ones, and was the 310th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 341 studies in Autoimmune Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study followed by an optional open-label extension to evaluate the efficacy and safety of sibeprenlimab 400 mg administered SC Q4 weeks as an add-on to background treatment in participants with Sjögren's disease.

The primary objective is to compare the effect of sibeprenlimab versus placebo added to background treatment on European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) scores at 28 weeks.

The key secondary objective is to compare the effect of sibeprenlimab versus placebo added to background treatment on European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index (ESSPRI) at 28 weeks.

Approximately 80 participants who have a diagnosis of Sjögren's disease according to the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria will be randomized with approximately 40 participants in the sibeprenlimab group and 40 participants in the placebo group.

03

Conditions studied

  • Sjogren Disease

Keywords

  • Sibeprenlimab
  • Autoimmune Diseases
  • Immune System Diseases
  • Dry Mouth
  • Dry Eyes
  • Salivary Gland Disorders
  • Lacrimal Gland Disorders
  • Immunoglobulin G
  • EnVISage
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed with Sjögren's disease.
  • ESSDAI score (which measures disease activity) must be 5 or higher.
  • Salivary flow rate must be at least 0.05 mL/min.
  • Serum IgG level must be higher than 900 mg/dL.
  • Must be able to communicate well with the investigator and agree to follow the trial requirements.
  • Participants can continue certain medications (hydroxychloroquine, methotrexate, leflunomide, or azathioprine) if they have been on a stable dose for at least 30 days.
  • dose must be stable and no more than 10 mg/day for at least 30 days.
  • Test positive for anti-Ro52 and/or anti-Ro60 antibodies.

Key Exclusion Criteria:

  • Another active rheumatic disease.
  • Prior use of B-cell depleting therapy or prohibited .
  • Significant comorbidities including uncontrolled type 2 diabetes, , and chronic and/or acute infections.
  • Suicidal ideation or behavior based on the Patient Health Questionnaire-9 (PHQ-9).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    400 mg Sibeprenlimab

    Biological: Sibeprenlimab

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalSibeprenlimab

    400 mg administered SC Q4 weeks

  • OtherPlacebo

    Administered SC Q4 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) score

    Higher scores on the ESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.

    Time frame: 28 weeks

Secondary outcomes

  1. Change from baseline in European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index (ESSPRI) score

    Higher scores on the ESSPRI indicate a worse outcome, as they reflect higher levels of patient-reported symptoms. Minimum value is 0, maximum value is 10.

    Time frame: 28 weeks

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: 28 weeks

  3. Incidence of treatment-emergent adverse events (TEAEs) by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade

    Time frame: 28 weeks

  4. Incidence of treatment-emergent adverse events (TEAEs) with an outcome of death

    Time frame: 28 weeks

  5. Incidence of serious treatment-emergent adverse events (TEAEs)

    Time frame: 28 weeks

  6. Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of the investigational medicinal product (IMP)

    Time frame: 28 weeks

  7. Proportion of participants with minimal clinical improvement defined as European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) reduction ≥ 3 points from baseline

    Higher scores on the ESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.

    Time frame: At 28 weeks

  8. Proportion of participants with minimal clinical improvement defined as European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index (ESSPRI) reduction ≥ 1 point from baseline

    Higher scores on the ESSPRI indicate a worse outcome, as they reflect higher levels of patient-reported symptoms. Minimum value is 0, maximum value is 10.

    Time frame: At 28 weeks

  9. Change from baseline in individual European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) domains

    Higher scores on the ESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.

    Time frame: At 28 weeks

  10. Change from baseline in salivary flow rate

    Time frame: At 28 weeks

  11. Change from baseline in tear flow rate

    Time frame: At 28 weeks

  12. Change from baseline in Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ClinESSDAI) score

    Higher scores on the ClinESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.

    Time frame: At 28 weeks

  13. Change from baseline in Physician Global Assessment (PhGA) score

    Higher scores on the PhGA indicate a worse outcome, as they reflect a higher assessment of disease activity or severity by the physician. Minimum value is 0 and the maximum value is 10.

    Time frame: At 28 weeks

  14. Change from baseline in Patient Global Assessment (PaGA) score of participant outcomes

    Higher scores on the PaGA indicate a worse outcome, as they reflect a higher assessment of disease severity or impact by the patient. Minimum value is 0 and the maximum value is 10.

    Time frame: At 28 weeks

  15. Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) score

    Higher FACIT-Fatigue scores indicate a better outcome, as they reflect less fatigue. Minimum value is 0 and the maximum value is 52.

    Time frame: At 28 weeks

  16. Change from baseline in 36 Item Short-Form Survey Version 2 (SF-36v2) Physical Component Summary Scale score and Mental Component Summary Scale score

    Higher scores on the SF-36v2 indicate a better outcome, as they reflect better health status and quality of life. Minimum value is 0 and the maximum value is 100.

    Time frame: At 28 weeks

  17. Change from baseline in patient-reported Sjögren's disease diary score

    Higher diary score indicates more severe symptoms and greater impact on the patient's daily life. Minimum value is 0 and the maximum value is 10.

    Time frame: At 28 weeks

  18. Proportion of participants with minimal clinical improvement, defined as Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) score increase of ≥ 4 from baseline

    Higher FACIT-Fatigue scores indicate a better outcome, as they reflect less fatigue. Minimum value is 0 and the maximum value is 52.

    Time frame: At 28 weeks

  19. Time to the first occurrence of minimal clinical improvement in ESSDAI

    Time frame: Week 28

  20. Time to the first occurrence of minimal clinical improvement in ESSPRI

    Time frame: Week 28

  21. Percent change from baseline in total serum IgA

    Time frame: Week 28

  22. Percent change from baseline in total serum IgG

    Time frame: Week 28

  23. Percent change from baseline in total serum IgM

    Time frame: Week 28

  24. Percent change from baseline in total serum free APRIL (a proliferation-inducing ligand) concentrations

    Time frame: Week 28

  25. Cmax of sibeprenlimab

    Time frame: 28 weeks

  26. Tmax of sibeprenlimab

    Time frame: 28 weeks

  27. Area Under the Curve (AUC) of sibeprenlimab

    Time frame: 28 weeks

  28. Serum concentration of sibeprenlimab

    Time frame: 28 weeks

  29. Presence or absence of serum antidrug antibody (ADA) to sibeprenlimiab

    Time frame: 28 weeks

07

Study locations

63 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 60 phase 2 interventional studies under Autoimmune Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 100. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 15, 2025
StartActual
Apr 23, 2025
Primary completionEst.
Mar 13, 2027
CompletionEst.
Jun 4, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Tufts University School of Dental Medicine · Boston, United States
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    1 site removed
    Show 1 removed
    • Tufts University School of Dental Medicine · Boston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06928142
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Apr 23, 2025
Primary completion
Mar 13, 2027 (estimated)
Completion
Jun 4, 2027 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sibeprenlimab

Start the discussion